|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Atherosclerosis | |||||
| Cardiovascular Diseases | |||||
| Hypercholesterolemia | |||||
| Hypertension | |||||
| Diabetes Mellitus | |||||
| Coronary Disease | |||||
| 2 | More general conditions related to this trial | ||||
| Arterial Occlusive Diseases | |||||
| Arteriosclerosis | |||||
| Dyslipidemias | |||||
| Endocrine System Diseases | |||||
| Glucose Metabolism Disorders | |||||
| Heart Diseases | |||||
| Hyperlipidemias | |||||
| Lipid Metabolism Disorders | |||||
| Metabolic Diseases | |||||
| Myocardial Ischemia | |||||
| Vascular Diseases | |||||
| 3 | Interventions listed in this trial | ||||
| hypoglycemic agents | |||||
| antihypertensive agents | |||||
| fibrates | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Clofibric Acid | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anticholesteremic Agents | |||||
| Antilipemic Agents | |||||
| Antimetabolites | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| National Institute on Aging (NIA) | |||||
| National Heart, Lung, and Blood Institute (NHLBI) | |||||